A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Seagen Inc.
Study ID
NCT01716806
Phase
PHASE2
Status
Completed

Conditions

  • Hodgkin Disease
  • Peripheral T Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • brentuximab vedotin — DRUG
    1.8 mg/kg every 3 weeks by IV infusion
  • bendamustine — DRUG
    70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
  • dacarbazine — DRUG
    375 mg/m\^2 every 3 weeks by IV infusion
  • nivolumab — DRUG
    3 mg/kg every 3 weeks by IV infusion

Study Details

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.

Key Dates

Start date
Oct 31, 2012
Status verified
May 2024
Primary completion
Apr 7, 2023
Completion
Sep 12, 2023

Study Design

Enrollment
131 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: Brentuximab Vedotin in HL Patients
  • Experimental: Part B: Brentuximab Vedotin + Dacarbazine in HL Patients
  • Experimental: Part C: Brentuximab Vedotin + Bendamustine in HL Patients
  • Experimental: Part D: Brentuximab Vedotin + Nivolumab in HL Patients
  • Experimental: Part E: Brentuximab Vedotin in HL Patients
  • Experimental: Part F: Brentuximab Vedotin in PTCL Patients

Primary Outcome Measure

Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) [ Time Frame: Up to 81 months ]

Locations (49)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35249-
University of South Alabama - Mitchell Cancer InstituteMobileAlabama36604-
Alaska Urological InstituteAnchorageAlaska99503-
Banner MD Anderson Cancer CenterGilbertArizona85234-
Arizona Cancer Center / University of ArizonaTucsonArizona85724-5024-
Arizona Oncology Associates, PC - HOPETucsonArizona85710-
Highlands Oncology GroupSpringdaleArkansasJ. Thaddeus Beck-
Providence St Joseph Medical CenterBurbankCalifornia91505-
City of Hope National Medical CenterDuarteCalifornia91010-
Wilshire Oncology Medical Group Inc.PomonaCalifornia91767-
Rocky Mountain Cancer Centers - AuroraAuroraColorado80012-
Florida Cancer AffiliatesTrinityFlorida34655-
IACT HealthColumbusGeorgia31904-
Georgia Cancer Specialists / Northside Hospital Cancer InstituteSandy SpringsGeorgia30341-
Rush University Medical CenterChicagoIllinois60612-
Illinois Cancer Specialists / Advocate Lutheran General HospitalNilesIllinois60714-
American Oncology Networks LLCBethesdaMaryland20817-
Karmanos Cancer Institute / Wayne State UniversityDetroitMichigan48201-
Minnesota Oncology Hematology P.A.MinneapolisMinnesota55404-
Nebraska Cancer SpecialistsOmahaNebraska68130-
Comprehensive Cancer Centers of NevadaLas VegasNevada89169-
Morristown Medical Center/ Carol G. Simon Cancer CenterMorristownNew Jersey07960-
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08903-
New York Oncology Hematology, P.C.AlbanyNew York12208-
Columbia University Medical CenterNew YorkNew York10032-
James P. Wilmot Cancer Center / University of Rochester Medical CenterRochesterNew York14642-
Oncology Hematology CareCincinnatiOhio45242-
James Cancer Hospital / Ohio State UniversityColumbusOhio43210-
Willamette Valley Cancer Institute and Research CenterEugeneOregon97401-
Northwest Cancer Specialists, P.C.TigardOregon97223-
Prisma HealthGreenvilleSouth Carolina29615-
Arlington Cancer CenterArlingtonTexas76012-
Texas Oncology - BedfordBedfordTexas76022-
Texas Oncology - Presbyterian Cancer Center DallasDallasTexas75231-
Texas Oncology - Denton SouthDentonTexasKurkul-
Texas Oncology - Fort Worth 12th AvenueFort WorthTexas76104-
Houston Methodist Cancer CenterHoustonTexas77030-
MD Anderson Cancer Center / University of TexasHoustonTexas77030-
Texas Oncology - LongviewLongviewTexas75601-
Texas Oncology - McAllenMcAllenTexas78503-
Texas Oncology - Seton WilliamsonRound RockTexas78665-
Virginia Cancer Specialists, PCFairfaxVirginia22031-
Virginia Commonwealth University Medical CenterRichmondVirginia23298-
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer CareSalemVirginia24153-
Shenandoah Oncology P.C.WinchesterVirginia22601-
Benaroya Research Institute/Virginia Mason Medical CenterSeattleWashington98101-
Swedish Cancer InstituteSeattleWashington98104-
Wenatchee Valley Medical CenterWenatcheeWashington98821-
Carbone Cancer Center / University of WisconsinMadisonWisconsin53792-

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, ALUniversity of South Alabama - Mitchell Cancer Institute· Mobile, ALAlaska Urological Institute· Anchorage, AKBanner MD Anderson Cancer Center· Gilbert, AZArizona Cancer Center / University of Arizona· Tucson, AZArizona Oncology Associates, PC - HOPE· Tucson, AZ

Related Studies